Minoxidil for Alopecia Areata

Verdict: Published with Warning

Across 2 PubMed studies, the evidence for Minoxidil in Alopecia Areata grades Tier C — weak evidence. Effective, but with safety or population caveats.

C 🟠 C Weak Evidence Published with Warning

🔬Why this grade7-layer evidence engine

⚖️

Scoring transparency

All scores computed by a 7-layer evidence engine — fully auditable
Raw score 0.66
D
C
B
A
S
← counter-evidence / ineffectiveeffective / strong evidence →
Final grade
C · Published with Warning
Confidence
78%
Broadly consistent
Evidence level
E3
Single MA (PMID 38796079 is SR not MA)

How strongly each layer supports this effect

lower = less supportive
L1 ExamineGlobal benchmark
0.50
L11 AI re-checkIndependent read
0.50
L2 PubMedPrimary literature
0.60
L3 MechanismPlausibility
0.65
L5 Clinical bodiesAuthoritative stance
0.85
Against Mixed Supports
View the full decision path (audit trail)
  1. compute_raw_score — 加權公式: L2×0.30 + L3×0.25 + L5×0.25 + L11×0.10 + L1×0.10 = 0.655
  2. tier_from_score — 依分數區間映射至 tier letter
  3. apply_hec_rules — 高品質 SR/MA 顯示 positive (1 篇 > 0 negative)
  4. tier_strict_requirement_check — Tier 條件達標,未降階
  5. detect_disputes — 偵測到 0 個 hard + 0 個 soft dispute
  6. decide_status — 依 tier + dispute 結果決定 status

📄PubMed studies (2)L2 · primary research & systematic reviews

Comparison of Efficacy of Topical Betamethasone Dipropionate and Topical Minoxidil in Patients With Alopecia Areata
PMID: 38623137 2024 Journal article n = 100
Finding: Betamethasone group achieved 74% Grade 3-4 response vs minoxidil 42% (p=0.001); minoxidil 5% was statistically significantly inferior to topical corticosteroid over 12 weeks.
Effect size: [object Object]
View on PubMed
Comparison of efficacy, safety and satisfaction of latanoprost versus minoxidil, betamethasone and in combination in patients with alopecia areata: A blinded multiple group randomized controlled trial
PMID: 36257912 2022 RCT (double-blind) n = 108
Finding: Combination betamethasone+latanoprost and latanoprost monotherapy produced greater regrowth than minoxidil monotherapy; minoxidil monotherapy was the weakest arm with significant difference vs combination groups (p<0.05).
Academic
View on PubMed

🏛️Regulatory & authoritative positionsL4/L5 · FDA / EMA / NIH ODS / Cochrane / Mayo …

L4a US FDA
Supportive
to regrow hair on the top of the scalp (vertex only, see pictures on side of carton) source↗
L4c UK NHS
Supportive
L4d TW TFDA / 衛福部
Supportive
醫師藥師藥劑生指示藥品 source↗
L5b Mayo Clinic
Supportive
L5c Cleveland Clinic
Supportive
L5d Harvard Health
Supportive
Some people with the condition will respond to topical preparations applied to the affected areas, including minoxidil (Rogaine) which may increase hair growth by accelerating the speed of the natural hair cycle and increasing the diameter of hairs that begin to grow. source↗
L5e Specialty Society (condition-mapped)
Supportive
PMID 100% verifiedevery citation checked via NCBI Entrez
🔬2 PubMed studiesindependently re-checked by multiple sub-agents
engine_version: v1.0 claim_id: CLM-COND-alopecia-areata-INT-minoxidil-001 繁體中文版 →